Last reviewed · How we verify
Oral Risperidone
Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.
At a glance
| Generic name | Oral Risperidone |
|---|---|
| Also known as | risperdal, Risperdal, Twinings English Breakfast tea, Pepsi Max beverage, placebo risperdal |
| Sponsor | Zogenix, Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Risperidone antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. This dual antagonism at both dopamine and serotonin receptors distinguishes atypical antipsychotics from first-generation agents and provides a broader therapeutic profile.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Irritability associated with autism spectrum disorder
- Behavioral disturbances in dementia
Common side effects
- Weight gain
- Sedation/somnolence
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Prolactin elevation/hyperprolactinemia
- Orthostatic hypotension
- Metabolic syndrome (dyslipidemia, hyperglycemia)
- Tachycardia
Key clinical trials
- Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects (PHASE1)
- Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia (PHASE2)
- Subjective Experience Following Psilocybin (PHASE2)
- Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) (PHASE2)
- Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use (PHASE2)
- A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia (PHASE2, PHASE3)
- Safety and Efficacy of MP-214 in Patients With Schizophrenia (PHASE2, PHASE3)
- A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Risperidone CI brief — competitive landscape report
- Oral Risperidone updates RSS · CI watch RSS
- Zogenix, Inc. portfolio CI